Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.47 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL894741 | 0.84 | SIRT2 (0.70) | SIRT2POLBCYP2C19KDM4EALDH1A1 | |
| SCHEMBL31511888 | 0.78 | CYP2C19 (0.54) | SIRT2POLBCYP2C19KDM4EALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL3600528 | 0.78 | SIRT2 (0.57) | SIRT2POLBCYP2C19KDM4EALDH1A1 | |
| Valine SCHEMBL27633784 | 0.78 | SLC7A5 (0.47) | POLBCYP2C19KDM4EALDH1A1MEN1 | |
| Anthranilamide SCHEMBL2985093 | 0.77 | SIRT2 (0.60) | SIRT2POLBCYP2C19KDM4EALDH1A1 | |
| Anthranilamide SCHEMBL2834554 | 0.77 | SLC7A5 (0.50) | KDM4EALDH1A1HPGDMAPTSLC7A5 | |
| Valine SCHEMBL2992340 | 0.76 | SLC7A5 (0.48) | POLBCYP2C19KDM4EALDH1A1RAB9A | |
| SCHEMBL9361714 | 0.75 | CYP2C19 (0.57) | SIRT2POLBCYP2C19KDM4EALDH1A1 | |
| Valine SCHEMBL20522584 | 0.74 | IRAK4 (0.55) | ALDH1A1NPC1RAB9AHPGDKMT2A | |
| SCHEMBL30621148 | 0.73 | TP53 (0.61) | SIRT2POLBKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060100461-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | RENOVIS, INC. | 2006-05-11 | — | — | US | disclosed |
| US-7005546-B2 | Acetamidobenzamide compounds for neurodegenerative disorders | RENOVIS, INC. (US) | 2006-02-28 | — | — | US | disclosed |
| US-20040266881-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | RENOVIS, INC. | 2004-12-30 | — | — | US | disclosed |
| US-6759433-B2 | FOR THERAPY OF PARKINSON'S DISEASE | RENOVIS, INC. | 2004-07-06 | — | — | US | disclosed |
| US-20030176510-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | RENOVIS, INC. | 2003-09-18 | — | — | US | disclosed |
| US-6509378-B2 | Parkinson's disease; ability to antagonize MPTP induced reduction in dopamine levels; amidation of the nitrobenzoyl halide with alkylamine | CENTAUR PHARMACEUTICALS, INC. | 2003-01-21 | — | — | US | disclosed |
| US-20010037040-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | RENOVIS, INC. | 2001-11-01 | — | — | US | disclosed |
| EP-0819113-B1 | BENZAMIDES FOR NEURODEGENERATIVE DISORDER TREATMENT | CENTAUR PHARMACEUTICALS INC (US) | 2001-06-27 | — | — | EP | disclosed |
| EP-1079820-A1 | BENZAMIDE THERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CENTAUR PHARMACEUTICALS, INC. (US) | 2001-03-07 | — | — | EP | disclosed |
| US-6194465-B1 | ADMINISTERING ACETAMIDO-, NITRO-, OR AMINO-MONO- OR DISUBSTITUTED N-ALKYL BENZAMIDE COMPOUNDS SUCH AS N-TERT-BUTYL-4-ACETAMIDOBENZAMIDE FOR PROPHLAXIS OR TREATMENT OF AN INFLAMMATORY BOWEL CONDITION IN A PATIENT | CENTAUR PHARMACEUTICALS, INC. | 2001-02-27 | — | — | US | disclosed |
| US-5914350-A | TREATING PARKINSON*S DISEASE | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-06-22 | — | — | US | disclosed |
| US-5907061-A | AMIDATION A NITROBENZOYLHALIDE WITH A SATURATED ALKYLAMINE TO FORM A DRUG TREATING PARKINSON'S DISEASE OR SLOW THE PROGRESSIVE LOSS OF FUNCTION | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-05-25 | — | — | US | disclosed |
| EP-0912171-A1 | BENZAMIDE TREATMENT OF DEMENTIA ASSOCIATED WITH AIDS VIRUS (HIV-1) INFECTION | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-05-06 | — | — | EP | disclosed |
| US-5756548-A | TREATMENT OF PARKINSON*S DISEASE | CENTAUR PHARMACEUTICALS, INC. (US) | 1998-05-26 | — | — | US | disclosed |
| EP-0819113-A1 | BENZAMIDES FOR NEURODEGENERATIVE DISORDER TREATMENT | CENTAUR PHARMACEUTICALS, INC. (US) | 1998-01-21 | — | — | EP | disclosed |
| WO-1997038684-A1 | BENZAMIDE TREATMENT OF DEMENTIA ASSOCIATED WITH AIDS VIRUS (HIV-1) INFECTION | CENTAUR PHARMACEUTICALS, INC. (US) | 1997-10-23 | — | — | WO | disclosed |
| US-5659082-A | Nitro- and aminobenzamide compounds for neurodegenerative disorders | CENTAUR PHARMACEUTICALS, INC. (US) | 1997-08-19 | — | — | US | disclosed |
| US-5658953-A | Pharmaceutical compositions of acetamidobenzamide compounds for neurodegenerative disorders | CENTAUR PHARMACEUTICALS, INC. (US) | 1997-08-19 | — | — | US | disclosed |
| US-5643965-A | TREATMENT OF DOPAMINE ASSOCIATED NERVOUS SYSTEM DISORDERS | CENTAUR PHARMACEUTICALS, INC. (US) | 1997-07-01 | — | — | US | disclosed |
| WO-1996031462-A1 | BENZAMIDES FOR NEURODEGENERATIVE DISORDER TREATMENT | CENTAUR PHARMACEUTICALS, INC. (US) | 1996-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266881-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | SNCA, PARK7, GBA1 | SIRT2 1265/4885POLB 468/4885CYP2C19 2072/4885 |
| US-20010037040-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | SNCA, PARK7, GBA1 | SIRT2 1265/4885POLB 468/4885CYP2C19 2072/4885 |
| US-20060100461-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | SNCA, PARK7, GBA1 | SIRT2 1265/4885POLB 468/4885CYP2C19 2072/4885 |
| US-20030176510-A1 | Acetamidobenzamide compounds for neurodegenerative disorders | SNCA, PARK7, GBA1 | SIRT2 1265/4885POLB 468/4885CYP2C19 2072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.